GlaxoSmithKline EC Grants Conditional Marketing OK For Votrient

15th Jun 2010 14:14

LONDON (Dow Jones)--GlaxoSmithKline PLC (GSK.LN), a global healthcare group, said Tuesday that the European Commission or EC has granted a conditional marketing authorization for Votrient--pazopanib for the first-line treatment of advanced Renal Cell Carcinoma and for patients who have received prior cytokine therapy for advanced disease. MAIN FACTS: -As part of these conditions, GSK will provide data from ongoing clinical studies. -The U.S Food and Drug Administration approved the use of Votrient--pazopanib as a treatment for patients with advanced RCC in October 2009. Shares at 1310 GMT up 6.0 pence, or 0.50%, at 1206.50 pence. -By Razak Musah Baba, Dow Jones Newswires; +44-20-7842-9275; [email protected] (END) Dow Jones Newswires June 15, 2010 09:14 ET (13:14 GMT)